| Valuation method | Value, £ | Upside, % |
|---|---|---|
| Artificial intelligence (AI) | 23.70 | 1294 |
| Intrinsic value (DCF) | 28.93 | 1602 |
| Graham-Dodd Method | n/a | |
| Graham Formula | n/a |
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.